The long‐acting anti‐C5 ravulizumab results in C3 binding to PNH red cells similar to its parental molecule eculizumab.

(A) C3d binding to PNH red cells in a PNH patient naïve to anti-C5 therapy who started ravulizumab. C3d binding to PNH red cells in a PNH patient naïve to anti-C5 therapy (left panel), during eculizumab treatment (middle panel) and after the switch to ravulizumab (right panel). [Extracted from the article]